Loading company…
Outrun Therapeutics develops protein-targeting therapies for cancer and other diseases.
Founded in 2019 and based in Scotland, Outrun Therapeutics develops therapeutic drugs using engineered protein sensor technology. Its platform generates E3 ligase inhibitors intended to stabilize proteins, including targets relevant to hard-to-treat solid tumors. In April 2024, it raised USD 10 million in seed funding from M Ventures and MP Healthcare Venture Management to support research and development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in